Making sense of dysautonomia, PoTS and Long COVID science one decoded article at a time.
Live Last read · last published · next check
The first global prevalence estimates of autonomic dysfunction in Long COVID are here. The numbers are larger than most clinicians suspect.
A 2026 study of 4,244 people with Long COVID, ME/CFS and other chronic conditions found that morning heart rate variability data could predict evening symptom severity with meaningful accuracy.
A 2024 study of 534 ME/CFS patients found that 91% showed abnormal reductions in brain blood flow and cardiac output when upright, despite passing the tilt table test with completely normal results.
A 2026 study looked directly into the cerebrospinal fluid of ME/CFS patients and found proteins linked to Alzheimer’s, blood clotting and immune activation. Here is what that actually means.
A study published this month used advanced MRI to map microstructural brain changes in ME/CFS and Long COVID and the findings are hard to dismiss.
Lets take a detailed look at 10 treatments currently in trials or emerging evidence, what stage they are at, and what the pros and cons actually are.
Semaglutide improved one patient’s PoTS significantly. Tirzepatide made another dramatically worse. Both are GLP-1 receptor agonists. Here is why that actually makes biological sense.
Creatine has spent decades being associated with gym bags and protein shakes. A growing body of research suggests it might have a role in one of the most debilitating symptoms of ME/CFS and Long COVID
A new research review investigates whether SARS-CoV-2 nudges the body toward cancer biology... and the honest answer is complicated
PEM is one of the most debilitating and least understood features of Long COVID, ME/CFS and dysautonomia. New research is finally starting to map the mechanisms. Here is what we know.
